This inventor holds 3 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent. Top assignees: Shanghai Novamab Biopharmaceuticals Co., Ltd., Shanghai Novamab Biopharmaceuticals Co., Ltd.. Active years: 2024-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 3 
1 out of 1 Years Active: 2024-2026
Title: Innovations of Junwei Gai in Biopharmaceuticals
Introduction
Junwei Gai is a prominent inventor based in Shanghai, China, known for his significant contributions to the field of biopharmaceuticals. He holds two patents that focus on innovative antibody technologies aimed at addressing critical health issues.
Latest Patents
One of his latest patents is an anti-interleukin-4 receptor (IL-4R) single-domain antibody, which includes a coding polynucleotide and methods for its application in IL-4R detection and disease treatment. This invention details a single-domain antibody that specifically recognizes human and marmoset IL-4R, while showing no recognition of mouse IL-4R. The antibody effectively inhibits the proliferation of TF-1 cells and the activation of the pSTAT6 signaling pathway in cells. Another notable patent is a blocking type PD-L1 single-domain camel antibody, which can be utilized for treating, preventing, or diagnosing PD-L1 related diseases, including tumors.
Career Highlights
Junwei Gai is currently associated with Shanghai Novamab Biopharmaceuticals Co., Ltd., where he continues to advance his research and development efforts in the biopharmaceutical sector. His work is characterized by a strong focus on antibody-based therapies that have the potential to transform treatment protocols for various diseases.
Collaborations
He collaborates with notable colleagues such as Yakun Wan and Min Zhu, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Junwei Gai's innovative work in the field of biopharmaceuticals, particularly through his patents on single-domain antibodies, showcases his commitment to advancing medical science and improving patient outcomes. His contributions are paving the way for new therapeutic approaches in the treatment of diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile